(Q38058760)

27 August 2017

title

Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk (English)

1 reference

27 August 2017

Ok-Nam Bae

1

1 reference

27 August 2017

publication date

1 October 2012

1 reference

Archives of Pharmacal Research

27 August 2017

published in

1 reference

27 August 2017

volume

35

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1693-1699

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-012-1000-3

27 August 2017

exact match

0 references

cites work

An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Future innovations in anti-platelet therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Discovery and development of therapeutic aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

von Willebrand factor: an emerging target in stroke therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Targeting von Willebrand factor and platelet glycoprotein Ib receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Platelets in inflammation and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Anti-platelet therapy: phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

A Structural Explanation for the Antithrombotic Activity of ARC1172, a DNA Aptamer that Binds von Willebrand Factor Domain A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Antiplatelet therapy: in search of the 'magic bullet'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Aptamers as candidate therapeutics for cardiovascular indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Inhibitors of platelet adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Triggers, targets and treatments for thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Antiplatelet therapies for the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Investigational drugs in thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

VWF attributes--impact on thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

The role of von Willebrand factor in thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Gastrointestinal effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

von Willebrand factor, endothelial dysfunction, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

Platelets in Inflammation and Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1000-3

10.1007/S12272-012-1000-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1007171755

0 references

1 reference